Phase 3 Trial Finds Daraxonrasib Extends Median Survival to 13 Months vs 7 Months for Chemotherapy in Second-Line Pancreatic Cancer

A Phase 3 trial of daraxonrasib enrolled 500 people whose pancreatic cancer had progressed after one round of standard treatment. The study compared once-daily oral daraxonrasib with conventional chemotherapy and was published in the New England Journal of Medicine on Sunday.

Daraxonrasib halted or reversed tumor progression in nearly a third of patients, while chemotherapy achieved the same outcome in 10 percent.

Median survival reached roughly 13 months in the daraxonrasib group and remained under seven months in the chemotherapy group. The results drew a standing ovation at the American Society of Clinical Oncology annual meeting in Chicago the same day they were released. Dr.

Who attended the meeting, said, “My first reaction was: This is a well-deserved standing ovation. ” Dr. Jennifer Knox, a medical oncologist specializing in pancreatic cancer at the Princess Margaret Cancer Centre in Toronto who also attended the meeting, said, “It is the biggest breakthrough for pancreatic cancer ever.

Pancreatic cancer carries a 13 percent five-year survival rate. More than nine in 10 cases are driven by a mutation in the KRAS gene. Daraxonrasib belongs to a new class of RAS(ON) inhibitors designed to target that mutation.

Roughly 14 percent of patients on daraxonrasib developed a rash. Menta “Steve” Wallace, a 74-year-old pancreatic cancer patient from Houston, Texas, participated in a follow-on trial and said his last scan showed his tumor had shrunk by nearly 50 percent.

The trial’s principal investigator, Dr. ” Dr. Gyawali noted that a doubling of survival time in pancreatic cancer “has never happened” until now, though he added that daraxonrasib remains a second-line treatment and not a cure.

U.S. Food and Drug Administration. Revolution Medicines stated it is actively preparing regulatory submissions globally.

More than 7,000 new cases of pancreatic cancer are diagnosed each year in Canada, and the disease kills upwards of 6,000 Canadians annually, according to the Canadian Cancer Society.